
    
      This is a multicenter, single-arm, extension study in which adults with secondary
      hyperparathyroidism currently receiving hemodialysis and previously treated in Amgen studies
      20120231 (NCT01785875), 20120334 (NCT01576146), or 20120360 (NCT01896232) will continue to be
      treated with etelcalcetide until approximately 2.5 years after the first participant was
      enrolled.
    
  